**Core Concept**
The rate-limiting step in cholesterol biosynthesis occurs in the mevalonate pathway, where HMG CoA reductase catalyzes the conversion of HMG CoA to mevalonate. This step is tightly regulated and is the primary target for statin therapy due to its pivotal role in cholesterol production.

**Why the Correct Answer is Right**
HMG CoA reductase catalyzes the NADPH-dependent reduction of HMG CoA to mevalonate, which is the committed and rate-limiting step in the cholesterol biosynthesis pathway. This enzyme is allosterically regulated by sterols and is subject to feedback inhibition by cholesterol and its derivatives. Its activity determines the flux through the entire pathway, making it the key regulatory enzyme.

**Why Each Wrong Option is Incorrect**
Option A: HMG CoA synthetase is involved in the early steps of ketone body synthesis and fatty acid metabolism, not cholesterol biosynthesis. It is not rate-limiting.
Option C: Thiokinase (e.g., succinyl-CoA synthetase) is involved in the TCA cycle and energy production, not cholesterol synthesis.
Option D: Mevalonate kinase catalyzes the phosphorylation of mevalonate in the mevalonate pathway but is downstream and not rate-limiting.

**Clinical Pearl / High-Yield Fact**
HMG CoA reductase is the target of statins, which inhibit this enzyme to reduce LDL cholesterol. Its activity is upregulated by low cholesterol and downregulated by high cholesterol, making it a key player in lipid metabolism regulation.

✓ Correct Answer: B. HMG CoA reductase